Becton, Dickinson and Company (BD) has recently released its 10-Q report, detailing its operations and financial performance for the first quarter of fiscal year 2026. BD is a global medical technology company engaged in the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. The company operates through five distinct segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences.
In the latest financial report, BD reported worldwide revenues of $5.252 billion for the first quarter of fiscal year 2026, marking a 1.6% increase from the prior-year period. The increase in revenues was attributed to various factors, including volume/other impacts, pricing, and foreign currency effects.
BD's cash flows from operating activities were $657 million during the first three months of fiscal year 2026. The company had $1.035 billion in cash and equivalents and short-term investments, including restricted cash, as of December 31, 2025. BD continued to return value to its shareholders through cash dividends and stock repurchases, with approximately $299 million paid out in dividends and around $250 million spent on common stock repurchases during the period.
The company highlighted that its operations, supply chain, suppliers, and customers are exposed to various global macroeconomic factors and other risks, which could potentially impact its operations and financial results. BD mentioned that it has been experiencing adverse impacts to its results of operations due to market dynamics in China, reductions or delays in governmental research funding, and lower demand for vaccines, among other factors.
In terms of segment performance, BD's Medical Essentials segment reported revenues of $1.595 billion for the first quarter of 2026, reflecting a 0.6% increase from the prior-year period. The Connected Care segment's revenues stood at $1.131 billion, marking a 5.5% increase from the same period in the previous year. The BioPharma Systems segment reported revenues of $429 million, representing a 2.7% increase from the first quarter of 2025.
BD also provided insights into the operating income of its segments. The Medical Essentials segment's income for the first quarter of 2026 was $569 million, with a segment income as a percentage of Medical Essentials revenues at 35.6%. The Connected Care segment reported a segment income of $352 million, with a segment income as a percentage of Connected Care revenues at 31.1%. The BioPharma Systems segment's income was $140 million, with a segment income as a percentage of BioPharma Systems revenues at 32.6%.
These financial insights provide a comprehensive overview of BD's recent performance and its positioning in the global medical technology industry. As a result of these announcements, the company's shares have moved -0.59% on the market, and are now trading at a price of $207.11. If you want to know more, read the company's complete 10-Q report here.
